NCT05968599 2026-02-25
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Pfizer
Completed
Clinical Trials
22 trialsNCT04717154 2026-01-06
INSPIRE
Radboud University Medical Center
Phase 2 Completed
NCT04428788 2025-12-22
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Celgene
Phase 1 Completed
NCT05293496 2025-10-14
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
MacroGenics
Phase 1 Completed
NCT04381832 2025-07-22
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Arcus Biosciences, Inc.
Phase 1/2 Completed
NCT02204072 2025-07-15
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
Boehringer Ingelheim
Phase 1 Completed
NCT03822845 2025-04-17
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
University of Iowa
Phase 2/3 Completed
NCT02625857 2025-02-03
Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Completed
NCT03248570 2024-11-20
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
University of California, San Francisco
Phase 2 Completed
NCT05520138 2024-09-27
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
Pfizer
Completed
NCT03016312 2024-08-09
IMbassador250
Hoffmann-La Roche
Phase 3 Completed
NCT03017417 2024-07-18
COMRADE
Sheffield Teaching Hospitals NHS Foundation Trust
Phase NA Completed
NCT03389451 2024-07-12
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
University of Iowa
Phase 2/3 Completed
NCT03927391 2024-06-12
REDOSE
Radboud University Medical Center
Phase 4 Completed
NCT03388346 2024-02-15
68Ga PSMA in Preprostatectomy Patients
University of Iowa
Phase 2/3 Completed
NCT03551782 2022-02-25
A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Completed
NCT02398526 2021-11-02
PARABO
Bayer
Completed
NCT02450812 2021-11-02
URANIS
Bayer
Completed
NCT03563014 2020-05-20
BELFIGO
Bayer
Completed
NCT02162836 2020-04-27
A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Pharmaceutical K.K.
Phase 1 Completed
NCT02899104 2020-03-31
Navigant
Bayer
Completed
NCT01171729 2010-08-11
Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer
Samsung Medical Center
Phase 1/2 Completed